STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (OP-94)	GATUZOSIRAN
PRONUNCIATION	ga too" zoe sir' an
THERAPEUTIC CLAIM	Treatment of Metabolic dysfunction-associated steatohepatitis (MASH) and Chronic alcohol-related liver disease (ALD)

CHEMICAL NAMES

RNA, ([1′-de(6-amino-9*H*-purin-9-yl)]dA-(5′→5′)-sp-Cm-Gm-Um-Am-Am-Gm-Am-Am-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)G-Am-Um-Am-Gm-Am-Um-Gm-Am-(3′→3′)-sp-[1′-de(6-amino-9*H*-purin-9-yl)]dA), 3′-[*O*-[*cis*-4-[(3*S*,8*S*)-17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,8-bis[[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]carbonyl]-1,6,11-trioxo-15-oxa-2,7,12-triazaheptadec-1-yl]cyclohexyl] hydrogen phosphorothioate], complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)C-sp-Am-sp-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Am-Um-Cm-Am-Gm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)U-Am-(2′-deoxy-2′-fluoro)C-sp-Gm) (1:1)

all-P-ambo-[(2*R*,3*S*)-2-(Hydroxymethyl)oxolan-3-yl] hydrogen 5'-*O*-({[(2*R*,3*S*)-3-({[(*cis*-4-{(3*S*,8*S*)-17-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-3,8-bis[(2-{2-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]ethoxy}ethyl)carbamoyl]-6,11-dioxo-15-oxa-2,7,12-triazaheptadecan-1-oyl}cyclohexyl)oxy]hydroxyphosphorothioyl}oxy)oxolan-2-yl]methoxy}hydroxyphosphorothioyl)-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyl-*P*-thio-3'-adenylate duplex with *all-P-ambo* 2'-*O*-methyl-*P*-thioguanylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(5'→3')-2'-*O*-methyluridine

STRUCTURAL FORMULA



MOLECULAR FORMULA	$C_{493}H_{653}F_{11}N_{163}O_{311}P_{43}S_7$
MOLECULAR WEIGHT	15603.75
TRADEMARK	None as yet
SPONSOR	GSK
CODE DESIGNATIONS	GSK4532990B
CAS REGISTRY NUMBER	2409783-34-0
UNII	K5P487RKV3
WHO NUMBER	13156

GBK